miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Cobomarsen expansion indication data released; first observations from the ongoing Phase 1 clinical trial on safety and efficacy of cobomarsen in ATLL patients, additional data expected by year end New cobomarsen Phase 1 data in CTCL released, Phase 2 …